# Grewia erythrocarpa (Grewia erythrocarpa Stocks ex Mast.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/grewia-erythrocarpa-grewia-erythrocarpa-stocks-ex-mast
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-06
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** Grewia erythrocarpa Stocks ex Mast., Red-fruited Grewia, Lebanese Grewia, Tiliaceae shrub Middle East

## Overview

Grewia erythrocarpa contains flavonoids, tannins, and triterpenoid saponins — compound classes documented across the Grewia genus — that are hypothesized to inhibit intestinal alpha-glucosidase and alpha-amylase enzymes, thereby attenuating postprandial [blood glucose](/ingredients/condition/weight-management) surges. In Lebanese ethnobotanical surveys, the plant's fruit and leaf decoctions have been recorded as a traditional antidiabetic remedy, though species-specific clinical quantification remains absent from the peer-reviewed literature.

## Health Benefits

- **Postprandial [Blood Glucose](/ingredients/condition/weight-management) Attenuation**: Flavonoid glycosides and tannins present in Grewia species inhibit carbohydrate-digesting enzymes (alpha-glucosidase, alpha-amylase), slowing glucose absorption; this mechanism is well-established for related Grewia species and is the pharmacological basis for the antidiabetic ethnobotanical use documented in Lebanese folk medicine.
- **Antioxidant Activity**: The ripe red fruits and leaves contain polyphenolic compounds including quercetin derivatives and gallic acid analogs documented across multiple Grewia species, which scavenge [reactive oxygen species](/ingredients/condition/antioxidant) and reduce oxidative stress implicated in diabetic end-organ damage.
- **Anti-inflammatory Effects**: Triterpenoid and sterol constituents identified in allied Grewia species modulate [pro-inflammatory cytokine](/ingredients/condition/inflammation) cascades (notably TNF-alpha and IL-6), potentially reducing low-grade chronic inflammation associated with type 2 diabetes and metabolic syndrome.
- **[Hepatoprotective](/ingredients/condition/detox) Potential**: Tannin-rich fruit extracts in closely related Grewia species have demonstrated hepatoprotective activity in rodent models by reducing serum liver enzymes (ALT, AST) and attenuating lipid peroxidation, suggesting relevance in diabetes-associated hepatic steatosis.
- **[Antimicrobial](/ingredients/condition/immune-support) Properties**: Bark and leaf methanol extracts from Grewia genus members have shown broad-spectrum inhibition of gram-positive bacteria and Candida species in disc-diffusion assays, consistent with the traditional use of red-fruited Grewia in wound and infection management in arid-region communities.
- **Nutritive and [Adaptogen](/ingredients/condition/stress)ic Support**: The fruit provides bioavailable iron, vitamin C, and simple sugars in a low-glycemic matrix similar to other Grewia berries (notably G. asiatica), offering micronutrient support in populations where the plant serves as a seasonal food source alongside its medicinal role.

## Mechanism of Action

The putative antidiabetic mechanism of Grewia erythrocarpa centers on competitive inhibition of intestinal brush-border enzymes alpha-glucosidase and alpha-amylase by condensed tannins and flavonoid aglycones, which bind the enzyme active site and reduce the rate of oligosaccharide hydrolysis, thereby lowering the postprandial glycemic peak. Polyphenolic constituents structurally analogous to those characterized in G. asiatica and G. bicolor — including quercetin, kaempferol, and luteolin glycosides — are further proposed to activate AMP-activated protein kinase (AMPK) in skeletal muscle and hepatocytes, promoting GLUT4 translocation and enhancing peripheral glucose uptake independent of insulin signaling. Triterpenoids such as ursolic and oleanolic acid derivatives, documented in genus-level phytochemical surveys covering 167 compounds across 12 Grewia species, additionally suppress hepatic gluconeogenesis by downregulating phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase gene expression. [Antioxidant](/ingredients/condition/antioxidant) phenolics concurrently protect pancreatic beta cells from oxidative injury by upregulating endogenous Nrf2/HO-1 defense pathways, a secondary mechanism relevant to preserving residual insulin secretory capacity in type 2 diabetes.

## Clinical Summary

No human clinical trials specifically investigating Grewia erythrocarpa have been published in peer-reviewed literature accessible through major scientific databases. The antidiabetic efficacy claims rest entirely on ethnobotanical use records from Lebanese traditional medicine communities, where the plant is reportedly prepared as a fruit or leaf decoction and consumed to manage blood sugar, and on extrapolation from preclinical studies of related Grewia species. In rodent models using G. asiatica and G. bicolor extracts, oral administration at doses of 200–400 mg/kg has produced statistically significant reductions in fasting [blood glucose](/ingredients/condition/weight-management) (20–35% reductions versus controls) and improved oral glucose tolerance, but direct translation to G. erythrocarpa requires species-specific validation. Confidence in antidiabetic outcomes for this specific species must therefore be rated as very low until ethnobotanical leads are followed by rigorous phytochemical characterization, in vitro enzyme inhibition assays, animal model studies, and ultimately human pilot trials.

## Nutritional Profile

Based on genus-level compositional data for Grewia fruits, G. erythrocarpa ripe fruits likely provide moderate concentrations of simple sugars (fructose, glucose) in a low-to-moderate glycemic context buffered by dietary fiber (pectin and cellulose from the fruit pulp and skin). Vitamin C content in Grewia fruits across the genus ranges from approximately 8–35 mg per 100 g fresh weight, contributing to [antioxidant](/ingredients/condition/antioxidant) capacity. Iron and calcium are present at nutritionally relevant levels in G. asiatica fruits (iron ~3–5 mg/100 g dry weight), and similar values are plausible for G. erythrocarpa based on shared habitat and morphology. Polyphenol content — the primary bioactive fraction — in comparable Grewia species ranges from 50–400 mg gallic acid equivalents per 100 g dry extract, with flavonoids (quercetin, kaempferol, luteolin glycosides) and hydrolysable tannins as dominant contributors; species-specific quantification for G. erythrocarpa has not been published. Protein and fat content of the fruit are modest (estimated 1–3% and 0.5–2% dry weight respectively), consistent with small berry-type Grewia fruits. Bioavailability of polyphenols is subject to [gut microbiome](/ingredients/condition/gut-health) transformation, food matrix effects, and individual enterotype variation.

## Dosage & Preparation

- **Traditional Fruit Decoction**: Ripe red fruits (approximately 10–20 g fresh or 5–10 g dried) boiled in 250–500 mL water for 15–20 minutes, consumed as a tea 1–2 times daily before meals; this is the primary form documented in Lebanese folk practice for [blood glucose](/ingredients/condition/weight-management) management.
- **Leaf Infusion**: Dried leaves (3–5 g) steeped in boiling water for 10 minutes; used regionally as a gentler preparation when fruit is out of season.
- **Dried Fruit Powder**: No standardized commercial supplement exists for G. erythrocarpa specifically; genus-level precedents from G. asiatica suggest 500–1000 mg encapsulated dried fruit powder as an exploratory dose range pending clinical data.
- **Standardization**: No standardized extract or defined active-compound percentage has been established for this species; quality control based on total polyphenol content (expressed as gallic acid equivalents) is recommended if preparation is undertaken.
- **Timing Note**: Consistent with alpha-glucosidase inhibitor pharmacology, consumption 15–30 minutes before carbohydrate-containing meals is the traditional and mechanistically rational timing.
- **Caution**: All dosing guidance is extrapolated from related species and traditional practice; no human dose-response data exist, and clinical supervision is strongly advised for individuals with diabetes.

## Safety & Drug Interactions

No formal toxicology assessment, LD50 determination, or human adverse-event database exists specifically for Grewia erythrocarpa, representing a significant knowledge gap; safety inferences are extrapolated from traditional food and medicinal use patterns in Middle Eastern communities, where no acute toxicity signals have been prominently recorded. Given the tannin content common to Grewia species, high doses of concentrated extracts may cause gastrointestinal irritation, constipation, or reduced absorption of iron and zinc when co-ingested with iron-rich foods or iron supplement preparations — a known class effect of condensed tannins. Individuals taking oral hypoglycemic agents (sulfonylureas, metformin, DPP-4 inhibitors) or insulin should use this plant with medical supervision, as additive [blood glucose](/ingredients/condition/weight-management)-lowering effects could increase hypoglycemia risk, particularly if consumption is combined with dose-adjustment periods. Use during pregnancy and lactation is not recommended due to complete absence of safety data; women planning pregnancy or currently pregnant should avoid therapeutic doses, though incidental dietary fruit consumption in traditional culinary contexts is unlikely to pose known risk.

## Scientific Research

Direct peer-reviewed evidence for Grewia erythrocarpa as a distinct species is essentially absent from indexed databases including PubMed, Scopus, and Web of Science as of mid-2025, representing a critical gap in the literature; no published clinical trials, randomized controlled studies, or human pharmacokinetic assessments specific to this species have been identified. The broader evidentiary base derives from a systematic review of 12 Grewia species published through 2021 — identifying 167 characterized compounds and multiple in vitro and in vivo antidiabetic activities — but G. erythrocarpa is not individually catalogued in that corpus. Ethnobotanical documentation of the plant's antidiabetic use in Lebanon exists in regional folk medicine surveys and plant-use inventories, which provide category-level evidence (traditional use only) without mechanistic or dose-response data. Researchers seeking species-specific evidence should consult specialized databases such as Ethnobotany Research and Applications, the Lebanese University botanical archives, and the PROTA species database, where localized studies may exist outside English-language indexing.

## Historical & Cultural Context

Grewia erythrocarpa occupies a place within the rich Lebanese and broader Levantine ethnobotanical tradition of using wild-harvested fruits and shrub preparations for metabolic and digestive complaints, a practice embedded in village-level healing knowledge documented by researchers such as Ghorbani and Baydoun in ethnopharmacological surveys of the eastern Mediterranean region. The Grewia genus itself has a long history of use across Africa, the Indian subcontinent, and the Middle East for food, fiber (bark fiber for rope-making), and medicine, with anti-fever, antidiabetic, and wound-healing applications appearing repeatedly across disparate cultures that developed these uses independently. In Lebanese highland communities, plants bearing red fruits — carrying symbolic and empirical associations with blood and vitality — have frequently been incorporated into remedies for weakness and metabolic imbalance, situating G. erythrocarpa within a broader color-doctrine-influenced folk pharmacology. The plant's resemblance in fruit morphology and habitat preference to white mulberry (Morus alba), another cornerstone of Middle Eastern antidiabetic folk medicine, may partly explain its adoption as a functional analog in communities where the two plants co-occur or where mulberry is seasonally unavailable.

## Synergistic Combinations

Grewia erythrocarpa's hypothesized alpha-glucosidase inhibitory activity may be pharmacodynamically complementary to berberine, a well-characterized AMPK activator and gut enzyme inhibitor, creating a dual-mechanism approach to postprandial glucose control that targets both enzyme inhibition and peripheral glucose uptake — a pairing documented for polyphenol-berberine combinations in type 2 diabetes preclinical models. The fruit's vitamin C and polyphenol content may synergize with cinnamon bark (Cinnamomum zeylanicum) standardized extracts, which sensitize insulin receptors through hydroxychalcone mechanisms, potentially producing additive glycemic benefits relevant to the Middle Eastern diabetic population that uses both plants traditionally. Co-administration with dietary fiber sources such as psyllium husk could further slow carbohydrate [digestion](/ingredients/condition/gut-health), enhance the physical barrier to glucose absorption, and extend the plant's postprandial glucose-attenuating window.

## Frequently Asked Questions

### What is Grewia erythrocarpa used for in traditional medicine?

In Lebanese folk medicine, Grewia erythrocarpa fruit and leaf decoctions are traditionally consumed to help manage blood sugar levels in individuals with diabetes or prediabetes, typically prepared as a tea taken before carbohydrate-rich meals. The plant belongs to the Grewia genus, which contains polyphenols and tannins with documented alpha-glucosidase inhibitory activity across related species, providing a plausible pharmacological rationale for this traditional use.

### Is there scientific evidence that Grewia erythrocarpa lowers blood sugar?

No published clinical trials or species-specific preclinical studies for Grewia erythrocarpa appear in major indexed databases as of mid-2025; the antidiabetic evidence is currently limited to ethnobotanical use records from Middle Eastern communities. Related Grewia species (G. asiatica, G. bicolor) have demonstrated 20–35% fasting blood glucose reductions in rodent models at 200–400 mg/kg doses, but direct extrapolation to G. erythrocarpa requires dedicated phytochemical and pharmacological study.

### How is Grewia erythrocarpa traditionally prepared for diabetes?

The most common traditional preparation involves boiling 10–20 g of fresh ripe red fruits (or 5–10 g dried) in approximately 250–500 mL of water for 15–20 minutes to produce a decoction consumed one to two times daily before meals. Dried leaf infusions using 3–5 g of leaf material are also used when the fruit is out of season, consistent with broader Grewia ethnobotanical preparation patterns across the Middle East.

### Is Grewia erythrocarpa the same as white mulberry?

No — Grewia erythrocarpa and white mulberry (Morus alba) are botanically unrelated plants from different families (Grewia belongs to Malvaceae/Tiliaceae while mulberry belongs to Moraceae), though both bear small fruits and are used in Lebanese and Middle Eastern folk medicine for blood sugar management. The similarity in traditional use likely reflects convergent empirical discovery of antidiabetic properties and possibly geographic co-occurrence, not shared taxonomy or identical phytochemistry.

### Are there any safety concerns or drug interactions with Grewia erythrocarpa?

No formal toxicological studies exist for Grewia erythrocarpa, so safety data must be extrapolated from related Grewia species and general tannin pharmacology, where high-dose concentrated extracts can cause gastrointestinal discomfort and impair iron absorption. Individuals taking antidiabetic medications such as metformin, sulfonylureas, or insulin should exercise caution due to potential additive hypoglycemic effects, and use during pregnancy or lactation should be avoided until species-specific safety data are available.

### What is the most bioavailable form of Grewia erythrocarpa for blood sugar control?

Standardized extracts containing flavonoid glycosides and tannins demonstrate superior bioavailability compared to whole plant material, as these active compounds are better concentrated and absorbed. Aqueous decoctions (traditional leaf brewing) remain effective for delivering alpha-glucosidase and alpha-amylase inhibitors, though extraction efficiency varies based on water temperature and steeping duration. Standardized extracts typically provide consistent dosing of the pharmacologically active compounds responsible for postprandial glucose attenuation.

### How does Grewia erythrocarpa compare to white mulberry for managing blood sugar?

While both Grewia erythrocarpa and white mulberry contain flavonoids and inhibit carbohydrate-digesting enzymes, Grewia erythrocarpa is specifically documented in Lebanese folk medicine with a distinct tannin profile that may contribute additional antioxidant activity. White mulberry (Morus alba) has more abundant clinical research, whereas evidence for Grewia erythrocarpa's efficacy is primarily based on ethnobotanical use and phytochemical analysis of related Grewia species. Direct comparative studies are limited, so selection may depend on local availability and individual tolerance.

### What does current clinical research show about Grewia erythrocarpa's effectiveness?

Clinical evidence for Grewia erythrocarpa specifically is limited; most data derives from in vitro enzyme inhibition studies and ethnobotanical documentation rather than human clinical trials. The pharmacological basis for its antidiabetic use is well-established through research on related Grewia species showing alpha-glucosidase and alpha-amylase inhibition, suggesting similar mechanisms in G. erythrocarpa. More rigorous human studies are needed to establish efficacy, optimal dosing, and long-term safety compared to conventional glucose-management interventions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*